Esaxerenone and Hypertension – A recent study has revealed that a new drug, esaxerenone, may be a promising treatment for high blood pressure. Researchers compared esaxerenone to a commonly used medication, trichlormethiazide, in a 12-week trial involving over 500 Japanese patients.
The results, published in Hypertension Research, showed that esaxerenone was as effective as trichlormethiazide in controlling blood pressure. However, esaxerenone was particularly good at reducing morning blood pressure, which is often a challenging aspect of hypertension management.
READ ALSO
- One in Five People Living with HIV in Sub-Saharan Africa Have High Blood Pressure, New Study Finds
- High Blood Pressure Activities to Avoid 2024
- Can Hibiscus Tea (Zobo) Cure Hypertension?
- Lower Blood Pressure Fast: Pharmacist & Community Health Worker Programs
Esaxerenone and Hypertension
The study also found that esaxerenone was as safe as trichlormethiazide. These findings suggest that esaxerenone could be a valuable alternative for patients with high blood pressure.
High blood pressure, or hypertension, is a silent killer affecting over a billion people worldwide. This condition significantly increases the risk of heart disease, stroke, and kidney problems. While many treatments are available, controlling blood pressure remains a challenge in many populations.
A prime example is Japan, where despite the availability of various anti-hypertensive drugs, only about 35% of people with high blood pressure have their condition under control. This starkly contrasts with countries like Korea and Taiwan, where the rate is much higher. This discrepancy has puzzled researchers, leading to the term “hypertension paradox.”
Experts believe the key to addressing this issue lies in finding new and more effective treatments. One promising drug in development is esaxerenone. This medication belongs to a class of drugs known as mineralocorticoid receptor blockers and has shown promise in earlier studies. However, its effectiveness in the Japanese population is still unknown.
The EXCITE-HT study involved over 500 Japanese patients with uncontrolled high blood pressure. Participants were randomly assigned to receive either esaxerenone or trichlormethiazide in addition to their existing blood pressure medication.
After 12 weeks, patients taking esaxerenone experienced a greater reduction in morning blood pressure compared to those taking trichlormethiazide. This is significant because morning blood pressure is a key factor in heart health. Esaxerenone was found to be equally safe as trichlormethiazide. These findings suggest that esaxerenone could be a valuable new option for treating high blood pressure in Japan. While the results are promising, more research is needed to confirm these findings in larger studies and over longer periods.
